Adenovirus 5 Produces Obesity and Adverse Metabolic, Morphological, and Functional Changes in the Long Term in Animals Fed a Balanced Diet or a High-fat Diet: a Study on Hamsters
Overview
Authors
Affiliations
Adenovirus 5 (Ad-5) infection is a common cause of acute respiratory infections and the main vector used in gene therapy. There are few studies on the relationship of Ad-5 to obesity. In the present study, we evaluated the chronic effects of Ad-5 infection on golden (Syrian) hamsters fed either a balanced diet (BD) or a high-fat diet (HFD). After a single inoculation with Ad-5 (1 × 10 pfu), the body weight of the animals was measured weekly. Medium-term (22 weeks) serum biochemical analyses and long-term (44 weeks) liver morphology, adiposity, and locomotive functionality (movement velocity) assessments were carried out. In the animals fed the BD, adenovirus infection produced hyperglycemia and hyperlipidemia. In the long term, it produced a 57% increase in epididymal pad fat and a 30% body weight gain compared with uninoculated animals. In addition, morphological changes related to non-alcoholic fatty liver disease (NAFLD) were observed. The animals fed the HFD had similar but more severe changes. In addition, the hamsters presented an obesity paradox: at the end of the study, the animals that had the most morphological and functional changes (significantly reduced movement velocity) had the lowest body weight. Despite the fact that an HFD appears to be a more harmful factor in the long term than adenovirus infection alone, infection could increase the severity of harmful effects in individuals with an HFD. Epidemiological studies are needed to evaluate the effect of adenovirus as a precursor of chronic liver and cardiovascular diseases, including the chronic effects of gene therapy.
Adenovirus-5 and adenovirus-37 seropositivity in obese patients.
Bostan N, Altinok O, Suleyman B, Alis H, Oner Y Iran J Microbiol. 2024; 16(5):684-688.
PMID: 39534296 PMC: 11551655. DOI: 10.18502/ijm.v16i5.16804.
Cortes-Alvarez S, Delgado-Enciso I, Rodriguez-Hernandez A, Hernandez-Fuentes G, Aurelien-Cabezas N, Moy-Lopez N J Nutr Metab. 2024; 2024:2209581.
PMID: 38375319 PMC: 10876314. DOI: 10.1155/2024/2209581.
Mendoza-Hernandez M, Guzman-Esquivel J, Ramos-Rojas M, Santillan-Luna V, Sanchez-Ramirez C, Hernandez-Fuentes G Vaccines (Basel). 2024; 12(1).
PMID: 38250885 PMC: 10821037. DOI: 10.3390/vaccines12010072.
The Use of Viral Vectors for Gene Therapy and Vaccination in Tuberculosis.
Mata-Espinosa D, Lara-Espinosa J, Barrios-Payan J, Hernandez-Pando R Pharmaceuticals (Basel). 2023; 16(10).
PMID: 37895946 PMC: 10610538. DOI: 10.3390/ph16101475.
mRNA: Vaccine or Gene Therapy? The Safety Regulatory Issues.
Banoun H Int J Mol Sci. 2023; 24(13).
PMID: 37445690 PMC: 10342157. DOI: 10.3390/ijms241310514.